Cheryl Carter
Family · Sebring, FLNPI 1174571525
Payments from drug & device makers
Across 390 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Bayer$673
- Corcept Therapeutics$653
- Boehringer Ingelheim$576
- AbbVie$408
- plus $4K from 36 others
What the payments were for
- Food & beverage$8,651100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $1,388 |
| Novo Nordisk | 60 | $1,118 |
| Bayer | 26 | $673 |
| Corcept Therapeutics | 21 | $653 |
| Boehringer Ingelheim | 28 | $576 |
| AbbVie | 16 | $408 |
| Axsome Therapeutics, Inc. | 8 | $356 |
| Sanofi-aventis U.S. LLC | 19 | $350 |
| Amgen | 17 | $300 |
| Novartis | 15 | $278 |
| Lilly USA, LLC | 15 | $271 |
| Exact Sciences | 12 | $238 |
| Xeris Pharmaceuticals, Inc. | 10 | $215 |
| Dexcom, Inc. | 8 | $173 |
| Otsuka America Pharmaceutical, Inc. | 8 | $163 |
| Esperion Therapeutics, Inc. | 5 | $152 |
| Merck | 7 | $152 |
| Abbott | 6 | $126 |
| Bausch Health US, LLC | 6 | $126 |
| Johnson & Johnson | 5 | $101 |
| Phathom Pharmaceuticals, Inc. | 2 | $84 |
| Lundbeck LLC | 3 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $58 |
| Radius Health, Inc. | 3 | $55 |
| Mylan Specialty L.p. | 2 | $51 |
| Medtronic | 2 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $49 |
| Insulet Corporation | 2 | $47 |
| GSK | 2 | $42 |
| Cequr Corporation | 3 | $40 |
| Pfizer | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Antares Pharma, Inc. | 1 | $22 |
| Biogen | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,672 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $144,810 |
| JardianceEmpagliflozin | 80 | $108,022 |
| TrulicityDulaglutide | 58 | $103,087 |
| EliquisApixaban | 64 | $90,187 |
| FarxigaDapagliflozin Propanediol | 78 | $83,941 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 46 | $69,175 |
| MounjaroTirzepatide | 36 | $39,575 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $26,961 |
| MyrbetriqMirabegron | 16 | $19,721 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $18,286 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $17,890 |
| XareltoRivaroxaban | 16 | $16,782 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $15,013 |
| KerendiaFinerenone | 12 | $14,473 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $13,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,118 | $144,81091 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $271 | $142,66294 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,388 | $108,063116 claims |
| Boehringer IngelheimJardiance | $576 | $108,02280 claims |
| PfizerEliquis | $30 | $90,18764 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $350 | $69,17546 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $42 | $54,51367 claims |
| Johnson & JohnsonXarelto | $101 | $16,78216 claims |
| MerckJanuvia, Dulera | $152 | $16,47228 claims |
| BayerKerendia | $673 | $14,47312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Sebring
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.